27475106|t|Metabolic shift of the kynurenine pathway impairs alcohol and cocaine seeking and relapse
27475106|a|The glutamatergic system plays a key role in the maintenance of drug use and development of drug-related conditioned behaviours. In particular, hyper-glutamatergic activity and N-methyl-D-aspartate receptor (NMDAR) activation may drive drug craving and relapse. Inhibition of kynurenine-3-monooxygenase (KMO) shifts the metabolic kynurenine pathway towards production of kynurenic acid, which leads to a reduction of glutamatergic / NMDAR activity via different mechanisms. In this study, we investigated whether drug-seeking and relapse behaviour could be modified by the metabolic shift of endogenous kynurenine pathway. An inhibitor of kynurenine-3-monooxygenase (KMO) Ro61-8048 (4 and 40 mg/kg) and its prodrug JM6 (100 and 200 mg/kg) were tested in two behavioural rat models for drug seeking and relapse -the alcohol deprivation effect (ADE) model in long-term alcohol-drinking rats and the model of cue-induced reinstatement of alcohol- and cocaine-seeking behaviour. Our results show that relapse -like alcohol drinking during the ADE was abolished by repeated intraperitoneal administration of Ro61-8048 and significantly reduced by its oral prodrug JM6. Cue-induced reinstatement of both alcohol- and cocaine-seeking behaviour was also abolished by administration of Ro61-8048. Pharmacological enhancement of endogenous kynurenic acid levels provides a novel treatment strategy to interfere with glutamatergic / NMDAR activity as well as with craving and relapse in alcohol-dependent patients and drug addicts.
27475106	0	9	Metabolic	T040	C0025519
27475106	10	15	shift	T033	C3845720
27475106	23	33	kynurenine	T116,T123	C0022818
27475106	34	41	pathway	T169	C1291081
27475106	42	49	impairs	T169	C0221099
27475106	50	57	alcohol	UnknownType	C0813934
27475106	62	77	cocaine seeking	T048	C0600427
27475106	82	89	relapse	T067	C0035020
27475106	94	114	glutamatergic system	T043	C1523698
27475106	139	162	maintenance of drug use	UnknownType	C0678330
27475106	167	178	development	T169	C1527148
27475106	182	217	drug-related conditioned behaviours	UnknownType	C0814171
27475106	234	262	hyper-glutamatergic activity	T043	C1523698
27475106	267	296	N-methyl-D-aspartate receptor	T116,T192	C0080093
27475106	298	303	NMDAR	T116,T192	C0080093
27475106	305	315	activation	T043	C1514758
27475106	326	338	drug craving	T033	C0556446
27475106	343	350	relapse	T067	C0035020
27475106	352	362	Inhibition	T039	C1524081
27475106	366	392	kynurenine-3-monooxygenase	T116,T126	C0064449
27475106	394	397	KMO	T116,T126	C0064449
27475106	399	405	shifts	T033	C3845720
27475106	410	419	metabolic	T040	C0025519
27475106	420	430	kynurenine	T116,T123	C0022818
27475106	431	438	pathway	T169	C1291081
27475106	447	457	production	T169	C0205245
27475106	461	475	kynurenic acid	T109,T121	C0022816
27475106	494	503	reduction	T061	C0441610
27475106	507	520	glutamatergic	T043	C1523698
27475106	523	528	NMDAR	T116,T192	C0080093
27475106	529	537	activity	T044	C1152633
27475106	552	562	mechanisms	T169	C0441712
27475106	572	577	study	T062	C2603343
27475106	582	594	investigated	T169	C1292732
27475106	603	615	drug-seeking	T033	C0694536
27475106	620	627	relapse	T067	C0035020
27475106	628	637	behaviour	T053	C0004927
27475106	647	658	modified by	T080	C0205349
27475106	663	672	metabolic	T040	C0025519
27475106	673	678	shift	T033	C3845720
27475106	682	692	endogenous	T169	C0205227
27475106	693	703	kynurenine	T116,T123	C0022818
27475106	704	711	pathway	T169	C1291081
27475106	716	725	inhibitor	T121	C0919438
27475106	729	755	kynurenine-3-monooxygenase	T116,T126	C0064449
27475106	757	760	KMO	T116,T126	C0064449
27475106	762	771	Ro61-8048	T109,T121	C0670377
27475106	797	804	prodrug	T120	C0033262
27475106	805	808	JM6	T109,T121	C3178194
27475106	834	840	tested	T169	C0039593
27475106	848	870	behavioural rat models	T015	C0086893
27475106	875	887	drug seeking	T033	C0694536
27475106	892	899	relapse	T067	C0035020
27475106	905	931	alcohol deprivation effect	T033	C0243095
27475106	933	936	ADE	T033	C0243095
27475106	938	943	model	T015	C0086893
27475106	947	956	long-term	T079	C0443252
27475106	957	973	alcohol-drinking	T055	C0001948
27475106	974	978	rats	T015	C0086893
27475106	987	992	model	T015	C0086893
27475106	996	1007	cue-induced	UnknownType	C0679056
27475106	1008	1021	reinstatement	T079	C0678335
27475106	1025	1033	alcohol-	UnknownType	C0813934
27475106	1038	1063	cocaine-seeking behaviour	T048	C0600427
27475106	1087	1094	relapse	T067	C0035020
27475106	1101	1117	alcohol drinking	T055	C0001948
27475106	1129	1132	ADE	T033	C0243095
27475106	1159	1189	intraperitoneal administration	T061	C0021493
27475106	1193	1202	Ro61-8048	T109,T121	C0670377
27475106	1221	1228	reduced	T080	C0392756
27475106	1236	1240	oral	T082	C0442027
27475106	1241	1248	prodrug	T120	C0033262
27475106	1249	1252	JM6	T109,T121	C3178194
27475106	1254	1265	Cue-induced	UnknownType	C0679056
27475106	1266	1279	reinstatement	T079	C0678335
27475106	1288	1296	alcohol-	UnknownType	C0813934
27475106	1301	1326	cocaine-seeking behaviour	T048	C0600427
27475106	1349	1363	administration	T061	C1533734
27475106	1367	1376	Ro61-8048	T109,T121	C0670377
27475106	1378	1393	Pharmacological	T121	C1254351
27475106	1394	1405	enhancement	T052	C2349975
27475106	1409	1419	endogenous	T169	C0205227
27475106	1420	1434	kynurenic acid	T109,T121	C0022816
27475106	1435	1441	levels	T080	C0441889
27475106	1453	1477	novel treatment strategy	UnknownType	C0683465
27475106	1481	1495	interfere with	T169	C0521102
27475106	1496	1509	glutamatergic	T043	C1523698
27475106	1512	1517	NMDAR	T116,T192	C0080093
27475106	1518	1526	activity	T044	C1152633
27475106	1543	1550	craving	T033	C0556446
27475106	1555	1562	relapse	T067	C0035020
27475106	1566	1609	alcohol-dependent patients and drug addicts	UnknownType	C0687701